Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04855799 · ClinicalTrials.gov registry record · Phase 2
GI Permeability Change in Response to Aquamin®
A Phase 2 study, sponsored by James Varani.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT04855799 is a Phase 2 study that has completed, run by James Varani. The registered enrollment target is 35 participants.
The verdict
NCT04855799, a Phase 2 study, has completed, sponsored by James Varani.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
This trial is being completed to learn about how Aquamin® affects gastrointestinal permeability, or the control of material passing from inside the gastrointestinal tract through the gut wall into the rest of the body, in people with ulcerative colitis (UC), Irritable Bowel Syndrome with diarrhea (IBS-D), and in healthy individuals.
Interventions
- DRUG Aquamin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2021-11-02 |
| Est. Completion | 2024-03-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04855799
The ClinicalTrials.gov registry entry for NCT04855799 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is James Varani, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aquamin is the first listed.
NCT04855799 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04855799 about?
NCT04855799 is a clinical study titled "GI Permeability Change in Response to Aquamin®". This trial is being completed to learn about how Aquamin® affects gastrointestinal permeability, or the control of material passing from inside the gastrointestinal tract through the gut wall into the rest of the body, in people with ulcerative colitis (UC), Irritable Bowel Syndrome with diarrhea (I...
What is the current status of trial NCT04855799?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2021-11-02. Estimated completion is 2024-03-25.
What interventions are being tested in trial NCT04855799?
The interventions under investigation include: Aquamin (DRUG).
Who is sponsoring clinical trial NCT04855799?
This trial is sponsored by James Varani, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.